Phillip Parente
A5000291176- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Immunotherapy and Immune Responses
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Cancer, Lipids, and Metabolism
- CAR-T cell therapy research
- Cancer survivorship and care
- Multiple Myeloma Research and Treatments
- Prostate Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Melanoma and MAPK Pathways
- Gastric Cancer Management and Outcomes
- Hormonal and reproductive studies
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Cutaneous Melanoma Detection and Management
- Lung Cancer Diagnosis and Treatment
- Global Cancer Incidence and Screening
- vaccines and immunoinformatics approaches
- Economic and Financial Impacts of Cancer
- Immune Cell Function and Interaction
- Clinical practice guidelines implementation
- Childhood Cancer Survivors' Quality of Life
Monash University
2016-2025
Eastern Health
2016-2025
Box Hill Hospital
2012-2025
National Heart Foundation of New Zealand
2020
Parks Victoria
2020
Monash Health
2020
Melbourne Health
2018-2019
Institut Claudius Regaud
2017
Sidney Kimmel Comprehensive Cancer Center
2017
Epworth Hospital
2013
NY-ESO-1 is a “cancer-testis” antigen expressed in many cancers. ISCOMATRIX saponin-based adjuvant that induces antibody and T cell responses. We performed placebo-controlled clinical trial evaluating the safety immunogenicity of recombinant protein with adjuvant. Forty-six evaluable patients resected NY-ESO-1-positive tumors received three doses vaccine intramuscularly at monthly intervals. The was well tolerated. observed high-titer responses, strong delayed-type hypersensitivity...
Purpose Cabazitaxel 25 mg/m2 (C25) significantly improved overall survival (OS) versus mitoxantrone ( P < .001) in postdocetaxel patients with metastatic castration-resistant prostate cancer (mCRPC) the phase III TROPIC study. The PROSELICA study ClinicalTrials.gov identifier: NCT01308580) assessed noninferiority of cabazitaxel 20 (C20) C25 mCRPC. Methods Patients were stratified by Eastern Cooperative Oncology Group performance status, measurability disease per Response Evaluation Criteria...
The effectiveness of comprehensive geriatric assessment (CGA) in improving health outcomes cancer settings is unclear. We evaluated whether CGA can improve health-related quality life (HRQOL) older people with who are starting systemic anticancer treatment.INTEGERATE a multicentre, open-label, pragmatic, parallel-group, randomised controlled trial that was done at three hospitals Australia. Participants aged 70 years and solid or diffuse large B-cell lymphoma planned for chemotherapy,...
PURPOSE Epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for -mutant, metastatic non–small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum–based chemotherapy with or without pembrolizumab TKI-resistant, nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837 ). METHODS Adults...
12011 Background: Older people experience significant adverse effects of cancer and anti-cancer therapy due to age-related vulnerabilities, including medical, functional, cognitive, nutritional psychosocial issues. Comprehensive geriatric assessment management (CGAM) provides a powerful framework assess an older person’s health status offers coordinated, person-centered approach care. Despite its effectiveness, the uptake CGAM in oncology has been limited lack randomized evidence this...
BackgroundAfatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade afatinib plus paclitaxel superior outcomes versus switching to chemotherapy alone acquiring resistance erlotinib/gefitinib and monotherapy.Patients methodsPatients relapsed/refractory disease following ≥1 line of chemotherapy, whose tumors had progressed...
Recent phase III clinical trials have established the superiority of anti-PD-1 antibodies pembrolizumab and nivolumab over anti-CTLA-4 antibody ipilimumab in first-line treatment patients with advanced melanoma. Ipilimumab will be considered for second-line after failure therapy. We retrospectively identified a cohort 40 metastatic melanoma who received single-agent therapy or were treated on progression at dose 3 mg kg−1 maximum four doses. Ten percent achieved an objective response to...
PURPOSE Lifirafenib is an investigational, reversible inhibitor of B-RAF V600E , wild-type A-RAF, B-RAF, C-RAF, and EGFR. This first-in-human, phase I, dose-escalation/dose-expansion study evaluated the safety, tolerability, efficacy lifirafenib in patients with B-RAF– or K-RAS/N-RAS–mutated solid tumors. METHODS During dose escalation, adult histologically/cytologically confirmed advanced tumors received escalating doses lifirafenib. Primary end points were safety/tolerability during...
Abstract The combination of ipilimumab and nivolumab is a highly active systemic therapy for metastatic melanoma but can cause significant toxicity. We explore the safety efficacy this treatment in routine clinical practice, particularly setting serine/threonine‐protein kinase B‐Raf (BRAF)‐targeted therapy. Consecutive patients with unresectable stage IIIC/IV commenced on across 10 tertiary institutions Australia were identified retrospectively. Data collected included demographics, response...
Abstract Background. Multiethnic societies face challenges in delivering evidence-based culturally competent health care. This study compared health-related quality of life and psychological morbidity a hospital-based sample first-generation migrants Australian-born Anglo cancer patients, controlling for potential confounders related to migrant status. Further, it explored the relative contribution ethnicity versus migrant-related variables. Methods. Eligible participants, recruited via 16...
Access to exercise for cancer survivors is poor despite global recognition of its benefits. Telerehabilitation may overcome barriers but not routinely offered.Following the rapid implementation an exercise-based telerehabilitation program in response COVID-19, a process evaluation was conducted understand impact on patients, staff, and health service with aim informing future development.A mixed methods completed admitted between March December 2020. Interviews were patients staff involved...
There is increasing evidence showing the involvement of CD4 + T cells in initiating and maintaining antitumor immune responses. NY-ESO-1 expressed by various tumors but not normal tissues except testis. We conducted a cancer clinical trial using full-length protein formulated with ISCOMATRIX adjuvant injected into patients intramuscularly. Autologous dendritic pulsed combination overlapping synthetic peptides were used to identify immunodominant from vaccinated patient. show here...
Flt3 ligand mobilizes dendritic cells (DCs) into blood, allowing generation in vivo of large numbers DCs for immunotherapy. These immature can be rapidly activated by soluble CD40 (CD40L). We developed a novel overnight method using these cytokines to produce cancer ligand-mobilized (FLDCs) were isolated, with CD40L, loaded antigenic peptides from influenza matrix protein, hepatitis B core antigen, NY-ESO-1, MAGE-A4, and MAGE-A10, injected patients resected melanoma. Three injections given...
5008 Background: The Phase III TROPIC study (NCT00417079) reported a significant improvement in overall survival (OS) for C plus prednisone (P) (25 mg/m2once every 3 weeks 10 mg orally once daily) versus mitoxantrone P (Hazard Ratio [HR] 0.70; < 0.0001) pts with mCRPC previously treated D. This PROSELICA (NCT01308580) was designed to determine the relative efficacy and safety profile of C20 compared C25 P. Methods: In this randomized, open-label, multinational phase study, ECOG performance...
This trial aimed to provide estimates of effect and feasibility a physical activity intervention for hospitalized cancer survivors using smartwatches goal-setting feedback. A feasibility, single-blinded, randomized trial. Acute unit in tertiary hospital. Adult undergoing treatment (n = 24). Participants were usual care or 2 sessions behavioural goal setting Blinded assessments occurred at admission (T0), discharge (T1) 4-weeks post-discharge (T2). The primary outcome was...